TAO Synergies Inc. (TAOX)
| Market Cap | 43.84M |
| Revenue (ttm) | 207,333 |
| Net Income (ttm) | -26.96M |
| Shares Out | 7.13M |
| EPS (ttm) | -13.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 310,355 |
| Open | 7.16 |
| Previous Close | 7.58 |
| Day's Range | 6.00 - 7.21 |
| 52-Week Range | 1.84 - 11.98 |
| Beta | 2.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2025 |
About TAOX
TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex
NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced that options trading is now available on its four ...
TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation
November 18 at 12:15 p.m. ET—Bittensor expert James Altucher and Yuma CRO Evan Malanga dive deep into TAO, decentralized AI, and network outlook as TAO halving approaches TAO Synergies is the largest ...
Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms
Tradr ETFs has launched four new single-stock leveraged funds positioned to provide 2x (200%) the daily performance of their respective underlying stocks.
Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys
First-to-market funds seek to provide 200% long exposure on exciting growth stories NEW YORK , Nov. 13, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and pro...
Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys
Four funds represent first-to-market strategies offering 200% exposure on trending growth stocks NEW YORK , Nov. 11, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated inve...
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds
Seeks to optimize returns for shareholders while fostering evolution of Bittensor's decentralized machine intelligence marketplace NEW YORK , Nov. 4, 2025 /PRNewswire/ -- TAO Synergies Inc. (Nasdaq: T...
TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency
NEW YORK , Oct. 20, 2025 /PRNewswire/ -- TAO Synergies Inc. (Nasdaq: TAOX) ("TAO Synergies" or the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for...
TAO Synergies Announces $11 Million Private Placement
Financing supported by existing stockholders, TAO Strategy Advisor James Altucher, and new investor DCG NEW YORK , Oct. 13, 2025 /PRNewswire/ -- TAO Synergies Inc. (Nasdaq: TAOX) (the "Company"), a di...
TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)
New digital hub to educate, engage, and connect the growing TAO community and decentralized AI contributors NEW YORK , Sept. 22, 2025 /PRNewswire/ -- TAO Synergies Inc. (Nasdaq: TAOX) (the "Company"),...
TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event
Remarks focused on rapid growth of decentralized AI, top catalysts for Bittensor's ecosystem and TAO Synergies NEW YORK , Sept. 8, 2025 /PRNewswire/ -- TAO Synergies Inc. (Nasdaq: TAOX) (the "Company"...
TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy
Joseph Jacks to support Company's TAO pure-play treasury initiatives TAO treasury strategy anchored at intersection of decentralized AI and cryptocurrencies NEW YORK , Aug. 26, 2025 /PRNewswire/ -- TA...
TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today
New name and stock symbol highlight strategic commitment to TAO, the leading AI cryptocurrency NEW YORK , July 1, 2025 /PRNewswire/ -- TAO Synergies Inc. (Nasdaq: TAOX) (the "Company"), formerly Synap...
Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy
New trading symbol "TAOX" effective Tuesday, July 1, 2025, New name represents Company's strategic focus on the synergies between cryptocurrency and AI NEW YORK , June 26, 2025 /PRNewswire/ -- TAO Syn...
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking
Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK , June 24, ...
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token
Singular focus on Bittensor (TAO), the leading AI token by adoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO eq...
Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
$19.6 million in cash and cash equivalents as of September 30, 2024 Dramatically reduced cash burn rate expected NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogen...
Synaptogenix Announces $5.0 Million Financing
NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disor...
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK , July 18, 2024 /PRN...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis
Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synapto...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery
Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways NEW YORK , May 7, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) (...
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
NEW YORK , April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disor...
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK , April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging bioph...
Synaptogenix President Daniel L. Alkon, M.D.
Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SN...
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe...
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology
Acquires 25% stake in Cannasoul Analytics for up to $4 million to support R&D for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications Partners to drive development and com...